Gonadal steroids and bone metabolism in men

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 3, 2007, Pages 241-246

  Leder, Benjamin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Androgens; Bone metabolism; Estrogens; Male; Osteoporosis; Testosterone

Indexed keywords

ANDROGEN; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; GONADORELIN DERIVATIVE; LETROZOLE; PLACEBO; PRASTERONE; SEX HORMONE; TESTOSTERONE;

ANDROGEN THERAPY; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; DELAYED PUBERTY; GONAD; HORMONE ACTION; HORMONE RELEASE; HUMAN; OBSERVATIONAL STUDY; OSTEOPOROSIS; PROSPECTIVE STUDY; REVIEW; SHORT STATURE; STEROID BLOOD LEVEL; STEROID METABOLISM;

BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; GONADAL STEROID HORMONES; HUMANS; MALE; SEX FACTORS;

EID: 34247603109     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32814db87b     Document Type: Review

References (58)

1. Leder BZ, Finkelstein JS. Gonadal steroids and the skeleton in men: clinical aspects. In: Orwoll ES, Bliziotes M, editors. Osteoporosis: scientific principles and clinical aspects. Totawa: Humana Press Inc; 2002. pp. 393-411.
2. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26:833-876.
3. Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69:776-783.
4. Greenspan SL, Oppenheim DS, Klibanski A, et al. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989; 110:526-531.
5. Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386-2390.
6. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358-4365.
7. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-510.
8. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.
9. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689-3698.
10. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056-1061.
11. Bilezikian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339:599-603.
12. Leder BZ, LeBlanc KM, Schoenfeld DA, et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003; 88:204-210.
13. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106:1553-1560.
14. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004; 25:389-425.
15. Vanderschueren D, Venken K, Ophoff J, et al. Clinical Review: Sex steroids and the periosteum - reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab 2006; 91:378-382. This is a review of the literature from human and animal studies regarding the relative roles of androgens and estrogens in mediating periosteal bone expansion during pubertal development and in response to other stimuli.
16. van den Beld AW, de Jong FH, Grobbee DE, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000; 85:3276-3282.
17. Drinka PJ, Olson J, Bauwens S, et al. Lack of association between free testosterone and bone density separate from age in elderly males. Calcif Tissue Int 1993; 52:67-69.
18. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997; 12:1833-1843.
19. Khosla S, Melton LJ 3rd, Atkinson EJ, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86:3555-3561.
20. Khosla S, Melton LJ 3rd, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83:2266-2274.
21. Meier DE, Orwoll ES, Keenan EJ, et al. Marked decline in trabecular bone mineral content in healthy men with age: lack of association with sex steroid levels. J Am Geriatr Soc 1987; 35:189-197.
22. Murphy S, Khaw KT, Cassidy A, et al. Sex hormones and bone mineral density in elderly men. Bone Miner 1993; 20:133-140.
23. Rudman D, Drinka PJ, Wilson CR, et al. Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men. Clin Endocrinol (Oxf) 1994; 40:653-661.
24. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000; 133:951-963.
25. Center JR, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999; 84:3626-3635.
26. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, et al. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol (Oxf) 1998; 49:803-809.
27. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100:1755-1759.
28. Goemaere S, Van Pottelbergh I, Zmierczak H, et al. Inverse association between bone turnover rate and bone mineral density in community-dwelling men >70 years of age: no major role of sex steroid status. Bone 2001; 29:286-291.
29. Kenny AM, Gallagher JC, Prestwood KM, et al. Bone density, bone turnover, and hormone levels in men over age 75. J Gerontol A Biol Sci Med Sci 1998; 53:M419-M425.
30. Szulc P, Claustrat B, Marchand F, et al. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 2003; 88:5240-5247.
31. Barrett-Connor E, Mueller JE, von Muhlen DG, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85:219-223.
32. Boonen S, Vanderschueren D, Cheng XG, et al. Age-related (type II) femoral neck osteoporosis in men: biochemical evidence for both hypovitaminosis D- and androgen deficiency-induced bone resorption. J Bone Miner Res 1997; 12:2119-2126.
33. Gennari L, Gennari L, Merlotti D, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003; 88:5327-5333.
34. Goderie-Plomp HW, van der Klift M, de Ronde W, et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab 2004; 89:3261-3269.
35. Doran PM, Riggs BL, Atkinson EJ, et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001; 16:2118-2125.
36. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab 2006; 91:1336-1344. This definitive descriptive epidemiologic study reported the relationship between gonadal steroid levels and age in older men.
37. Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91:3908-3915. A combined cross-sectional and longitudinal approach describes the relationship between gonadal steroid levels and osteoporosis or bone loss in older men. The study utilized clinically relevant cut-offs for gonadal steroid levels and bone density.
38. Ensrud KE, Fullman RL, Barrett-Connor E, et al. Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study. J Clin Endocrinol Metab 2005; 90:1998-2004.
39. Ensrud KE, Lewis CE, Lambert LC, et al. Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. Osteoporos Int 2006; 17:1329-1336.
40. Mellstrom D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21:529-535. This epidemiologic study confirmed that free testosterone is an independent predictor of cortical BMD and previous osteoporosis-related fractures in elderly men.
41. Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 2006; 166:2124-2131. This longitudinal study reported a higher fall risk in men with lower bioavailable testosterone levels. The effect of testosterone level was independent of poorer physical performance.
42. Rosner W. Sex steroids and the free hormone hypothesis. Cell 2006; 124:455-456; author reply 456-457.
43. Eriksson AL, Lorentzon M, Mellstrom D, et al. SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab 2006; 91:5029-5037. This population-based study of two cohorts of men (elderly and young adult) demonstrated that polymorphisms in the SHBG promoter predict both serum levels of SHBG and hip BMD. Specifically, the genotype associated with higher levels of SHBG was also associated with higher BMD.
44. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122:751-762.
45. Evans SF, Davie MW. Low body size and elevated sex-hormone binding globulin distinguish men with idiopathic vertebral fracture. Calcif Tissue Int 2002; 70:9-15.
46. Legrand E, Hedde C, Gallois Y, et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone 2001; 29:90-95.
47. Martinez Diaz-Guerra G, Hawkins F, Rapado A, et al. Hormonal and anthropometric predictors of bone mass in healthy elderly men: major effect of sex hormone binding globulin, parathyroid hormone and body weight. Osteoporos Int 2001; 12:178-184.
48. Khosla S. Editorial: Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action? J Clin Endocrinol Metab 2006; 91:4764-4766.
49. Mauras N, O'Brien KO, Klein KO, et al. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000; 85:2370-2377.
50. Taxel P, Kennedy DG, Fall PM, et al. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 2001; 86:2869-2874.
51. Lee H, Finkelstein JS, Miller M, et al. Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2006; 91:1069-1075. This physiologic investigation demonstrated that both testosterone and estradiol mediate the increase in skeletal sensitivity observed in hypogonadal men.
52. Mauras N, Welch S, Rini A, et al. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004; 17:1597-1606.
53. Wickman S, Sipila I, Ankarberg-Lindgren C, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357:1743-1748.
54. Hero M, Norjavaara E, Dunkel L, et al. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:6396-6402.
55. Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91:2011-2016. This meta-analysis of the limited number of randomized placebo-controlled trials evaluates the efficacy of testosterone therapy in increasing BMD in men.
56. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355:1647-1659. This describes a 2-year, placebo-controlled, randomized, double-blind study of DHEA and testosterone therapy in elderly men and women (testosterone was given only to the men). DHEA's overall lack of efficacy is the major finding.
57. Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 2006; 91:2986-2993.
58. Muller M, van den Beld AW, van der Schouw YT, et al. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J Clin Endocrinol Metab 2006; 91:3988-3991.